DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) has received an average rating of “Moderate Buy” from the five analysts that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $12.00.

Several brokerages have recently weighed in on DMAC. Wall Street Zen raised shares of DiaMedica Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, June 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of DiaMedica Therapeutics in a report on Friday, July 17th. Finally, HC Wainwright restated a “buy” rating and issued a $12.00 price objective on shares of DiaMedica Therapeutics in a research report on Tuesday, August 11th.

Hedge Funds Weigh In On DiaMedica Therapeutics

A number of large investors have recently modified their holdings of DMAC. Squarepoint Ops LLC purchased a new stake in shares of DiaMedica Therapeutics in the second quarter valued at approximately $1,023,000. AWM Investment Company Inc. purchased a new position in DiaMedica Therapeutics in the second quarter worth $253,000. Bank of New York Mellon Corp acquired a new stake in DiaMedica Therapeutics in the second quarter valued at $829,000. Bank of America Corp DE lifted its holdings in DiaMedica Therapeutics by 62.5% in the first quarter. Bank of America Corp DE now owns 42,768 shares of the company’s stock valued at $290,000 after acquiring an additional 16,446 shares during the period. Finally, Renaissance Technologies LLC purchased a new stake in shares of DiaMedica Therapeutics during the 1st quarter worth $356,000. 10.12% of the stock is owned by hedge funds and other institutional investors.

DiaMedica Therapeutics Price Performance

Shares of NASDAQ DMAC opened at $7.83 on Friday. The stock has a fifty day moving average price of $6.74 and a 200 day moving average price of $6.60. DiaMedica Therapeutics has a 1-year low of $5.24 and a 1-year high of $10.42. The company has a market cap of $422.27 million, a PE ratio of -10.87 and a beta of 0.98.

DiaMedica Therapeutics (NASDAQ:DMAC) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.01. Analysts anticipate that DiaMedica Therapeutics will post -0.84 earnings per share for the current fiscal year.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for serious diseases with limited therapeutic options. The company’s research is centered on therapies intended to address neurological and kidney-related conditions.

DiaMedica’s lead product candidate is rinvecalin, also known as DM199, a recombinant form of human tissue kallikrein-1. The company is evaluating rinvecalin as a potential treatment for acute ischemic stroke and kidney diseases, including conditions involving impaired renal function.